<DOC>
	<DOCNO>NCT01119157</DOCNO>
	<brief_summary>This randomize , single-blinded , Phase IV , monocentric study healthy adult age &gt; 18 &lt; 60 year evaluate cellular humoral immunogenicity well reactogenicity intramuscular , inactivate , trivalent influenza vaccine , include aluminium adjuvanted whole virus vaccine , split vaccine subunit vaccine .</brief_summary>
	<brief_title>Comparison Cellular Humoral Immunogenicity , Safety Different Trivalent Influenza Vaccines</brief_title>
	<detailed_description>This randomize , single-blinded study vaccine prevention influenza . Three study visit schedule study subject , Day 0 , Day 9-11 Day 30-35 . Prior performance protocol procedure , investigator obtain informed consent participant . At first study visit ( Day 0 ) , demographic data , medical history , pre-existing condition concomitant medication record . Physical examination record vital sign perform case female childbearing age , pregnancy test perform . After subject qualify eligible , vaccination , 60 ml venous blood take base-line immunity test . Each subject randomly allocate receive one three study vaccine , administer deep intramuscular ( i.m . ) injection deltoid muscle . The subject blind vaccine regimen . The principal investigator administer vaccine fill ampoule pack pre-filled ready-to-use syrinx thus blind , staff sub-investigators responsible routine follow-up assessment laboratory personnel blind . A diary card give subject record pre-defined solicited adverse event vaccination day 6 subsequent day adverse event concomitant medication . At second study visit ( Day 9-11 ) diary card collect . All adverse event concomitant medication assess record . A physical examination perform 60 ml venous blood shall take immunity test . A new diary card give subject record adverse event concomitant medication . At third study visit ( Day 30-35 ) , diary card collect . All adverse event concomitant medication assess record . A physical examination perform 60 ml venous blood shall take immunity test .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy adult volunteer &gt; 18 &lt; 60 year age , sex ; Full contractual capacity participant Are good health ( determine vital sign medical history ) ; Negative urine serum pregnancy test female childbearing potential . If subject female childbearing potential , must use acceptable contraception method become pregnant duration study . ( Acceptable contraception include implant , injectables , combine oral contraceptive , effective intrauterine device ( IUDs ) , sexual abstinence , vasectomized partner ) ; Are able understand comply plan study procedure ; Signed informed consent prior initiation study procedure ; Absence existence exclusion criterion Known allergy egg OR component vaccine ( particular mercury ) ; History GuillainBarr√© syndrome ; Pregnancy OR breast feeding OR positive pregnancy test prior vaccination ; Immunosuppressive therapy precede 36 month ; Active neoplasm ( i.e . require form antineoplastic therapy ) ; Concomitant corticosteroid therapy , include inhaled corticosteroid . Local corticosteroid corticosteroid nasal spray permit . Psychiatric illness and/or concomitant psychiatric drug therapy may effect full contractual capacity participant ; Immunoglobulin ( similar blood product ) therapy within 3 month prior vaccination ; Vaccine therapy within 4 week prior study ; Influenza vaccination within 2 year prior study ; Chronic illness , opinion investigator , may interfere evaluation immune response ; Documented HIV , HBV HCV infection ; Acute febrile respiratory illness within one week prior vaccination ; Experimental drug therapy within 1 month prior vaccination ; Alcohol drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>influenza vaccine</keyword>
	<keyword>cellular immune response</keyword>
	<keyword>humoral immune response</keyword>
</DOC>